logo
I Was Told I Might Never Walk Again—so I Hiked a Volcano in Guatemala

I Was Told I Might Never Walk Again—so I Hiked a Volcano in Guatemala

Yahoo27-07-2025
I didn't let my lupus diagnosis stop me from hiking one of the highest peaks in Central America.
It was Christmas morning when I blinked awake to the mechanical beeping of a heart monitor.
At first, I thought I was dreaming. My heart thumped loudly in my chest. I tried to roll over and orient myself, but my limbs were numb, and everything around me was a blur of pale light and quiet panic. The voices outside my hospital room faded in and out until one finally broke through the fog. A man rushed in—the one who changed everything. His face said it before his words did.
'It's lupus,' he said.
I didn't know what that meant. I only knew it wasn't good.
I was 22 and had just been accepted to William & Mary, a top public university in the U.S. I had been the picture of health. A hiker. A wild-hearted, barefoot-loving soul who spent her weekends chasing sunrises and meaningful conversations. I had always been a thinker—someone who mapped out dreams and imagined every possible 'what if' scenario life could throw at me.
But even with all that imagination, nothing prepared me for the moment I stepped out of bed one morning and collapsed into my new reality.
Lupus is a chronic autoimmune disease. A body turned against itself. In a cruel twist of irony, after years of mentally picking myself apart, now my immune system was doing it for me—attacking perfectly healthy organs like they were intruders. It was a full-on war and I was losing. I was diagnosed with the worst class of it and told multiple times I might die. I almost did. The fatigue was relentless. The joint pain, unbearable. I received over nine blood transfusions just to keep me alive. The list of symptoms and restrictions, well, they were longer than my age.
Tied with IVs to the hospital bed for more than a month, I remember the doctor rattling off day in and day out what I could no longer do: no more sun exposure, swimming, hugging friends, eating at restaurants, playing with animals, gardening, and walking in dirt. Even walking unassisted, they warned, might not be in the cards. I had a compromised immune system and was supposed to live in a sanitary bubble if I was to live at all. It was like someone had compiled a list of everything that made me me, then crossed it all out.
I was a girl who ran and danced toward her dreams, tripping sometimes, but never stopping. Now, I was being told to sit still.
But I've never been very good at doing what I'm told.
And that's how I ended up 13,000 feet in the air, climbing Volcán Acatenango, one of Central America's highest peaks. The decision made no rational sense. Just months after being told I might never walk unassisted again, I was hiking into the sky on a path of volcanic ash and cloud-thin air.
At the same time, it was one of the most logical decisions I ever made.
Travel is so much more than movement and cool pictures in new places. It's how we reclaim pieces of ourselves. It's how we stretch beyond discomfort and fears and find out who other people are beyond our presumptions and who we are when no one else is around to define us.
I started the hike alongside a group of strangers—fellow adventurers whose names and stories I didn't know, but whose silent grit matched mine. There was something exhilarating about trekking next to people who knew nothing of my diagnosis, only my determination. After our bus dropped us off at the beginning of the trail, my heart sank. From the start, it was a slow, burning, upward climb. I am so glad I had no idea what lay ahead because I might have turned around right then and there. We passed through five microclimates in a day—humid jungle, alpine forest, wind-swept ridges, dry volcanic fields, and a cloud-pierced summit. Each shift was like stepping into another world entirely.
As we climbed, Acatenango's landscape shifted beneath our feet. The farmlands gave way to dense forests. The air thinned. My legs burned. My lungs ached. I slowed. And slowed again. I was often last in line, stopping frequently to rest, my legs almost crumbling under me.
And yet, I was still moving.
Stray dogs are abundant in the farmland, and a beautiful chocolate shepherd shared the journey with us. I soon realized what I hadn't shared with anyone, he probably knew. Out of the 20 of us, he stuck by my side, stopping when I paused and walking together with me when I began again.
When we reached base camp at 12,000 feet, I was shaking. My body throbbed. The trail narrowed and a dark windy fog quickly set in. I was surprised when our guide said our camp was just ahead because I could see nothing, not even a glowing light. It was icy cold. Where was Fuego, the elusive pillar of angry fire? We had been told there would be accommodations at the top. I didn't know whether to laugh or cry when I saw a stack of used mattresses, box springs, and shared sleeping bags. There was nothing sanitary about it, but it felt more healing than the hospital bed. We sipped hot chocolate around a flicker of a flame. I had come to see lava and was shivering around fading coals. But our guide was confident and told us we should wake up at 4 a.m. if we wanted to hike the remainder of the way to see Fuego up close and active.
I had plenty of experience staying awake through the night from my weeks in the hospital. I had no idea how I would pull myself out of bed this time. Luckily, I didn't even have to set an alarm. At 2 a.m, I awoke to cold, wet slobber. The puppy that walked with me had curled up on my pillow. Having shared the trek, he wanted to share the warmth, too. I was more than a little annoyed and sat straight up, trying to drag him off my corner of the mattress. I kicked open the wooden door of our makeshift hut to shove him out and came face-to-face with Fuego. In the deep mist of the night, I had no idea our camp was clinging to a slab of cliff right in front of the summit. The earth growled and Acatenango's fiery twin erupted in the distance. It was bright and brilliant and alive and somehow almost outdone by the thousands of shimmering stars framing it. The deep fog that had suffocated everything was peeled back like a curtain and I realized all the beauty that had been hiding underneath.
We rose for the summit. The final push. The hardest part. What seemed so close was a full three hours away still. A pillar of lava burst into the sky, glowing against the dusk. Around me, others gasped. Many reached for their phones and cameras. I stood in stunned silence. I wanted this image and memory etched in my mind before I tainted it with a camera lens.
The eruption lit up the sky again and again throughout the night and early morning. I had barely slept.
It was pitch black, and we were pushing through heavy sand and ash now. Two steps forward, a half step back. Mounds of crumbling dirt rose on either side, forming a slithering trail as we dipped down into the ravine and steadily rose up the other side. There was a moment, somewhere above the clouds, when I paused and turned around. The mountain where we camped, Acatenango, towered behind me, massive and ancient. Beneath its surface were deep, dark scars—grooves cut through the rock by old lava flows, now overgrown with stubborn green. I stood there, breathless from exertion and awe, already dripping sweat. I realized something that made me pause: The looming walls of dirt both engulfing me and forming my own path were the same. From the fog of sickness and the sting of IV needles, I was now coursing through the hazy vein of the mountain.
The same burning force that had once destroyed this path had also shaped it—created it, even. And now, I traced it. My own body, too, bore scars—seen and unseen. Pain had carved through me, but it had also made this journey possible. I wasn't walking despite my pain. I was walking with it and becoming something through it. I was, by every definition, weak. But I was so strong.
I was breathing hard—nearly wheezing—as the icy wind whipped against my face. My legs were leaden. My fingers were stiff and swollen. I stopped more than I moved. But I wasn't alone. Step by step, I made it to the top. There—at 13,045 feet—the sun rose above the world in every color imaginable—and some not even the most creative mind could fathom.
We stood in silence as clouds drifted below us and light spilled across the neighboring volcanic ridges—Agua Volcano to the left, Pacaya to the right. I was standing on Fuego in the shadow of Acatenango. Ironically, the name means 'Walled Place,' and here, I felt the walls placed around me come crumbling down. All I kept thinking was how everyone told me I couldn't—and how they weren't here to see this view. I reached my grimy, dirt-covered hand down to pet the dog in blatant defiance of my instructions not to be around or touch animals.
I didn't ever want to descend. The way down was almost harder than the trail up. I was slipping, sliding, and tumbling, joy erupting inside me.
Whether or not we realize it, we each travel every day—through grief, joy, and fire. We each have our own personal Fuegos and Acatenangos to face. Mine just happened to be a real one.
When I returned from Guatemala, my lupus didn't vanish. But I proved that 'can't' is just a word. Acatenango didn't cure me, but it reminded me my journey didn't end in a hospital bed. It started there.
It was Christmas morning when I blinked awake to the beeping of a heart monitor, my body a battlefield and my future a blur. But it was through the mist of the mountain where I really opened my eyes.
They told me I'd never hike again. That I might never walk unassisted. That I would have to live a smaller life, if I lived at all.
But they weren't there when the sky split open and fire danced across it.
They didn't see me rise through ash and altitude, gasping and shaking, clinging to a mountain that had known its own share of eruptions.
They didn't see the girl with IV scars, windburned cheeks, and dirt under her fingernails reach the summit with a dog by her side and a defiant heart in her chest.
I didn't conquer the mountain—I bled into it. Walking on the wounds it once carried, I learned how to live with mine. And when Fuego erupted, lighting the sky like a pulse, I knew I would never be the same. Not because I reached the summit, but because I learned I could keep rising—even while breaking.
Read the original article on Travel & Leisure
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run

Yahoo

timean hour ago

  • Yahoo

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run

Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Deion Sanders says he never questioned God during his battle with bladder cancer
Deion Sanders says he never questioned God during his battle with bladder cancer

Fox News

timean hour ago

  • Fox News

Deion Sanders says he never questioned God during his battle with bladder cancer

Deion Sanders revealed Monday he had his bladder removed after he was diagnosed with cancer, but he said he never questioned God, no matter how difficult things were. Sanders, 57, said God has blessed him too much to ask, 'Why me?' "I have never questioned God. You know my faith, man," Sanders said during an interview with Michael Irvin. "I never questioned and ask God. 'Why me?' I can't. Why me am I living like this? Why me am I the coach of the Colorado Buffaloes? Why me am I on this wonderful university? Why me do I have these wonderful kids with my last name? Like, why me that God has blessed me so much. Like, I would have to ask God, 'Why me all that, too?' "So, I never asked God, 'Why me?'" Sanders said he only asked the Lord to show him the way. "I only said, 'Lord, show me. Show me what you trying to do so I can help you expedite the process. Just show me. We got this, Lord. I know I ain't going nowhere,'" Sanders said. "I know for the enemy to try me, you had to say, 'Have you considered my servant crime?' You had to say that for him to even get to me. So I know that, I'm yours. I know what you going to do with me. I know what you going to continue to do with me." The bladder removal has forced Sanders to undergo a complete lifestyle change, which he said he reached out to someone for advice on how to deal with the changes. Sanders urged people to get checked, because he only discovered the cancer in the bladder after an ACT scan of his vascular pattern to determine if his blood clots were away. The Colorado head coach said it was "unbelievable" to be back talking to his players again. Colorado went 9-4 last season and will look to improve on that record this season after losing Heisman Trophy winner Travis Hunter and starting quarterback Shedeur Sanders to the NFL.

Option Care Health, Inc. (OPCH): A Bull Case Theory
Option Care Health, Inc. (OPCH): A Bull Case Theory

Yahoo

time2 hours ago

  • Yahoo

Option Care Health, Inc. (OPCH): A Bull Case Theory

We came across a bullish thesis on Option Care Health, Inc. on Brian's Substack by Brian Flasker. In this article, we will summarize the bulls' thesis on OPCH. Option Care Health, Inc.'s share was trading at $29.35 as of July 31st. OPCH's trailing and forward P/E were 23.29 and 19.65, respectively according to Yahoo Finance. A home infusion nurse in full PPE gown delivering treatments to a patient in their own home. Option Care Health (OPCH) has evolved into the dominant independent provider of home and alternate site infusion services in the U.S., originating from Madison Dearborn Partners' 2015 acquisition of Walgreens Infusion Services. The 2019 reverse merger with BioScrip and full divestiture by Walgreens and MDP by 2023 paved the way for OPCH to operate with full independence. Led by CEO John Rademacher and CFO Michael Shapiro, both with substantial equity stakes, OPCH has built a national infrastructure of 91 pharmacies and 99 infusion suites, covering 96% of the U.S. population. The company's integrated model provides cost-effective, high-quality infusion therapies in outpatient and home settings, capitalizing on a healthcare trend shifting treatments away from costly hospitals. This platform serves over 1,400 contracts with 800+ partners, including all top 10 national insurers. Acute therapies, though operationally complex, act as a competitive wedge, while chronic therapies anchor long-term recurring revenues. OPCH's mix—75% chronic, 25% acute—combined with a focus on generics and biosimilars, ensures resilience against pricing volatility. With its Advanced Practitioner (AP) model, OPCH is pushing clinical boundaries, managing more complex therapies in lower-cost settings and enhancing utilization of its already-built infrastructure. Only ~50% of its infusion suite capacity is currently utilized, leaving ample runway for capital-light growth. Despite industry concerns like drug pricing reforms and labor shortages, OPCH's embedded relationships, clinical capabilities, and scalable model offer strong visibility into cash flow and earnings. Trading at ~15.4x 2025 owner earnings with a 17.4% expected IRR, OPCH represents a high-quality compounder with an entrenched moat and significant upside. Previously, we covered a bullish thesis on Chemed Corporation by 310 Value in April 2025, which highlighted the durability of its earnings, temporary volatility in its subsidiaries, and disciplined share repurchases. The company's stock price has depreciated by approximately 29% since our coverage. This is because temporary segment headwinds persisted longer than expected. The thesis still stands as Chemed's core fundamentals remain intact. Brian Flasker shares a similar view but emphasizes OPCH's capital-light model and payer-aligned infrastructure. Option Care Health, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held OPCH at the end of the first quarter, which was 40 in the previous quarter. While we acknowledge the potential of OPCH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store